Breast cancer treatment: survival facts and associated side effects
Abstract
In the world the cancer is a prevailing disease therefore some rational and effective therapy required. The breast cancer is one of the most common cancers in a woman and now a day’s patients are increase. Therefore, development and research are ongoing on the effective treatment on breast cancer. The breast cancer treatment is depending on the cancer stage disease and risk, based on this therapeutic agent should be employed in the patients to protect the breast cancer disease. Such treatments are reducing the mortality and morbidity but constant monitoring of drug adverse effect. Moreover, it has been seen that the survival rates in breast cancer is rising that is good news for science but on the other side the side effects of the treatments bring new challenges. The early stage diagnosis of the breast cancer can survive the effective or healthy patient life because of long-term and various treatment can be employed on the cancer disease otherwise breast cancer is life threatening illness. Survivors of breast cancer have not only the side effects issues of the cancer therapy treatment but also, they have many other issues of previous treatments therefore it is challenging job for the researchers. Consequently, this review article is dealing with the breast cancer effective treatments and side effects of it. Moreover, it includes the other long-term medical issues after breast cancer diagnosis and treatment. This review will help to the researchers for better understanding of the long-term medical issues in the breast cancer.
References
2. Héry C, Ferlay J, Boniol M, Autier P. Changes in breast cancer incidence and mortality in middle-aged and elderly women in 28 countries with Caucasian majority populations. Annals of Oncology. 2008;19(5):1009-18.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA: a cancer journal for clinicians. 2008;58(2):71-96.
4. De Angelis R, Tavilla A, Verdecchia A, Scoppa S, Hachey M, Feuer EJ, et al. Breast cancer survivors in the United States: geographic variability and time trends, 2005-2015. Cancer. 2009;115(9):1954-66.
5. Rosedale M, Fu MR. Confronting the unexpected: temporal, situational, and attributive dimensions of distressing symptom experience for breast cancer survivors. Oncology nursing forum. 2010;37(1):E28-33.
6. Polyak K. Breast cancer: origins and evolution. The Journal of Clinical Investigation. 2007;117(11):3155-63.
7. Qadir MI, Malik SA. Plasma lipid profile in gynecologic cancers. European journal of gynaecological oncology. 2008;29(2):158-61.
8. Weigelt B, Geyer FC, Reis-Filho JS. Histological types of breast cancer: how special are they? Molecular oncology. 2010;4(3):192-208.
9. Sant M, Francisci S, Capocaccia R, Verdecchia A, Allemani C, Berrino F. Time trends of breast cancer survival in Europe in relation to incidence and mortality. International journal of cancer. 2006;119(10):2417-22.
10. Autier P, Boniol M, LaVecchia C, Vatten L, Gavin A, Héry C, et al. Disparities in breast cancer mortality trends between 30 European countries: retrospective trend analysis of WHO mortality database. BMJ. 2010;341:c3620.
11. Lukaszewicz K, Wtorek J, Bujnowski A, Skokowski J. Monitoring of breast tissue thermo-ablation by means of impedance measurements. Journal of Physics: Conference Series. 2010;224(1):012136.
12. Bhatt P, Lalani R, Vhora I, Patil S, Amrutiya J, Misra A, et al. Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation. International Journal of Pharmaceutics. 2018;536(1):95-107.
13. Patel J, Amrutiya J, Bhatt P, Javia A, Jain M, Misra A. Targeted delivery of monoclonal antibody conjugated docetaxel loaded PLGA nanoparticles into EGFR overexpressed lung tumour cells. Journal of Microencapsulation. 2018;35(2):204-17.
14. Yewale C, Baradia D, Patil S, Bhatt P, Amrutiya J, Gandhi R, et al. Docetaxel loaded immunonanoparticles delivery in EGFR overexpressed breast carcinoma cells. Journal of Drug Delivery Science and Technology. 2018;45:334-45.
15. Shockney LD. Perspectives on surveillance and survivorship: when to make the transition. Journal of the National Comprehensive Cancer Network : JNCCN. 2013;11(10):1298-302.
16. Lenihan DJ, Cardinale DM. Late cardiac effects of cancer treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(30):3657-64.
17. . Available from: https://www.cancer.gov/about-cancer
18. Wood ME, Vogel V, Ng A, Foxhall L, Goodwin P, Travis LB. Second malignant neoplasms: assessment and strategies for risk reduction. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(30):3734-45.
19. Paskett ED, Dean JA, Oliveri JM, Harrop JP. Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(30):3726-33.
20. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. JNCI: Journal of the National Cancer Institute. 1998;90(18):1371-88.
21. Silverman P. Book Review. New England Journal of Medicine. 2001;344(8):614-.
22. Vhora I, Patil S, Bhatt P, Misra A. Protein- and Peptide-drug conjugates: an emerging drug delivery technology. Advances in protein chemistry and structural biology. 2015;98:1-55.
23. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. Breast cancer. Clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2009;7(2):122-92.
24. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013;127(1):e6-e245.
25. Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. Journal of the National Cancer Institute. 2010;102(1):14-25.
26. Group EBCTC. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (London, England). 2005;365(9472):1687-717.
27. Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. Journal of the National Cancer Institute. 2012;104(17):1293-305.
28. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer treatment reviews. 2011;37(4):300-11.
29. Katz SJ, Hawley ST. From policy to patients and back: surgical treatment decision making for patients with breast cancer. Health affairs (Project Hope). 2007;26(3):761-9.
30. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998;16(2):441-52.
31. Harris EE, Correa C, Hwang WT, Liao J, Litt HI, Ferrari VA, et al. Late cardiac mortality and morbidity in early-stage breast cancer patients after breast-conservation treatment. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24(25):4100-6.
32. Nandur R, Kumar K, Villablanca AC. Cardiovascular Actions of Selective Estrogen Receptor Modulators and Phytoestrogens. Preventive Cardiology. 2004;7(2):73-9.
33. Vhora I, Patil S, Bhatt P, Gandhi R, Baradia D, Misra A. Receptor-targeted drug delivery: current perspective and challenges. Therapeutic delivery. 2014;5(9):1007-24.
34. Bhatt P, Lalani R, Mashru R, Misra A. Abstract 2065: Anti-FSHR antibody Fab’ fragment conjugated immunoliposomes loaded with cyclodextrin-paclitaxel complex for improved in vitro efficacy on ovarian cancer cells. Cancer Research. 2016;76(14 Supplement):2065-.
35. Lalani R, Bhatt P, Rathi M, Misra A. Abstract 2063: Improved sensitivity and in vitro efficacy of RGD grafted PEGylated gemcitabine liposomes in RRM1 siRNA pretreated cancer cells. 2016. 2063- p.
36. Bhatt P, Vhora I, Patil S, Amrutiya J, Bhattacharya C, Misra A, et al. Role of antibodies in diagnosis and treatment of ovarian cancer: Basic approach and clinical status. Journal of controlled release : official journal of the Controlled Release Society. 2016;226:148-67.
37. Bhatt P, Khatri N, Kumar M, Baradia D, Misra A. Microbeads mediated oral plasmid DNA delivery using polymethacrylate vectors: an effectual groundwork for colorectal cancer. Drug delivery. 2015;22(6):849-61.
38. Patil S, Lalani R, Bhatt P, Vhora I, Patel V, Patel H, et al. Hydroxyethyl substituted linear polyethylenimine for safe and efficient delivery of siRNA therapeutics. RSC Advances. 2018;8(62):35461-73.
39. Patil S, Bhatt P, Lalani R, Amrutiya J, Vhora I, Kolte A, et al. Low molecular weight chitosan–protamine conjugate for siRNA delivery with enhanced stability and transfection efficiency. RSC Advances. 2016;6(112):110951-63.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Innovative Science & Technology affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJIST.
Download link for COPYRIGHT FORM
